// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

18F-sodium fluoride positron emission tomography in acute aortic syndrome

Maaz Syed - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Acclean Plus

Multi-modality imaging in survivors of COVID-19

Trisha Singh - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Real world NHS experience of CTCA with FFRCT for the detection of surgical coronary artery disease - the case for enhanced pre-procedural planning?

David Murphy - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

Tissue doppler E’ velocity and E/e’ predict 19-year cardiovascular mortality in hypertension

Anenta Ramakrishnan - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

The prevalence of coronary artery disease in patients presenting to a rapid access chest pain clinic with ‘non-anginal chest pain’

Will Chick - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

Low-grade hypertension and coronary atherosclerosis in male master endurance athletes

gemma parry-williams - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

Association between high-sensitivity troponin and one year mortality in 20,000 consecutive hospital patients undergoing a blood test for any reason

Jonathan Hinton - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Effects of an established drug on smad signalling pathway in the rat model of monocrotaline pulmonary hypertension

Khaled Habas - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

Monocrotaline

Getting it right first time: CT coronary angiography first in GP patients referred to racpc – is it feasible?

John Graby - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Identification of familial hypercholesterolaemia in patients presenting with premature acute coronary syndrome

James Duff - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Hypercholesterolemia, Familial, 1

N/A

Prevalence of comorbidities and the incidence of cardiovascular disease in those with non-cardiac chest pain

Sai Ramesh - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Osteoarthritis

N/A

Association between carotid distensibility and heart rate variability in older age

Massimiliano Fornasiero - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Associations of non-alcoholic fatty liver disease with subclinical atherosclerosis and echocardiography measurements in young adults

Rosalind Tang - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Nonalcoholic fatty liver disease

N/A

The uclpartners proactive care frameworks – optimising cvd prevention post covid. innovation to restore and improve care in the high-risk conditions and prevent heart attacks and strokes at scale.

Matt Kearney - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

N/A

Nice 95 and non anginal chest pain: reassuring patients without investigation

Sarah Fellows - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Angina

N/A

Patients presenting with acute coronary syndromes have unreported coronary artery calcium on historical CT imaging

Conor Bradley - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute Coronary Syndromes

N/A

Introduction of a multidisciplinary cardiac metabolic clinic in a UK tertiary cardiology centre: early activity, interventions and potential for cardiovascular risk optimisation

Laura Bijman - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Intranasal glucagon

Primary care use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and cardiovascular disease – are we missing a trick?

David Higson - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Angiology

Peripheral artery disease

Simvastatin

Autonomic function in resistant and malignant hypertension

Reem Alsharari - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Malignant hypertension

N/A

Associations of triglyceride level and variabilities with lung related infections, cancer, and mortality outcomes: a territory-wide cohort study

Keith Sai Kit Leung - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Influenza

N/A

Copyright © 2026. QuantiNova All rights reserved